Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

China Shineway Pharmaceutical Group Ltd

CSWYF:PKC

China Shineway Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.00
  • Today's Change0.00 / 0.00%
  • Shares traded200.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 03 2024 19:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

China Shineway Pharmaceutical Group Limited is an investment holding company principally engaged in the research and development, manufacture and trading of modern Chinese medicines. Its main products include injections, soft capsules and granules. The Company’s subsidiaries include Yuan Da International Limited, Hong Zhan International Limited and Shineway Pharmaceutical Sales Company Limited.

  • Revenue in HKD (TTM)4.59bn
  • Net income in HKD1.21bn
  • Incorporated2002
  • Employees3.23k
  • Location
    China Shineway Pharmaceutical Group LtdLuanchengSHIJIAZHUANG 051430ChinaCHN
  • Phone+86 31 188030066
  • Fax+86 31 188030088
  • Websitehttp://www.shineway.com.hk
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.